Drug intelligence / Profile preview

SN50

Development stage
Preclinical
Lead developer
Selleck Chemicals
Modality
Peptides, Small Molecules
Administration
In Vitro, Ex Vivo, Experimental (cell Culture, Animal Models), Not Used Clinically In Humans
01

Overview

SN50 is a synthetic 41-residue cell-permeable peptide that functions as an inhibitor of nuclear factor kappa B (NF-κB) translocation. It consists of the hydrophobic region of the signal peptide from Kaposi fibroblast growth factor (K-FGF) attached to the nuclear localization sequence (NLS) of NF-κB p50. SN50 blocks NF-κB by competing with NF-κB complexes for the nuclear import machinery, thereby inhibiting the nuclear translocation of this transcription factor and suppressing downstream gene expression involved in inflammation, cell survival, and cancer. SN50 is primarily used as a research tool to explore NF-κB signaling in various disease contexts, including cancer and inflammatory diseases[1][2][3][8][9][11].

Other names
NF-κB SN50
02

Targets

NF-κB

Beyond the preview

Go deeper on SN50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SN50.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call